Capecitabine Market Size, Industry Share, Growth Trends and Forecasts (2023 - 2030)

By Form :

The form segment is categorized into tablets and powder. In 2022, the tablets segment accounted for the highest market share in the capecitabine market. Capecitabine tablets are easy to pack in travel dispensers per pack. This results in convenience fitting in a bag or pocket. Thus, the major advantage of a capecitabine tablet is its ease of use. In addition, the deployment of capecitabine tablets ensures high precision, dose accuracy, and lower variability, among others. Additionally, tablets are easier to swallow, and, in some cases, they can easily dissolve in water for feeding patients such as children. Capecitabine tablets are utilized for the treatment of lung cancer. For instance, according to the International Agency for Research on Cancer, a total of 1,470,274 new cases of cancer were recorded in Latin America in 2021. Among these, the most common type of cancer diagnosed in the region was lung cancer at 6.6%. Therefore, the increasing prevalence of lung cancers is fostering the demand for capecitabine tablets to ensure ease of use, which, in turn, is driving the market growth.

However, the powder segment is projected to be the fastest-growing segment during the forecast period. This is due to the increasing research and development activities for the adoption of the capecitabine powder at the global level, which is augmenting segmental growth.

By Indication :

The indication segment is categorized into breast cancer, colorectal cancer, gastric cancer, and others. In 2022, the breast cancer segment accounted for the highest market share in the capecitabine market and is expected to be the fastest-growing segment during the forecast period. Capecitabine is utilized by healthcare facilities to treat breast cancer that has reoccurred after previous treatment and has spread to the tissues & lymph nodes around the chest, neck, and others. Additionally, capecitabine is deployed for the treatment of early-stage triple-negative breast cancer. For instance, according to the recent statistics published by the Global Cancer Observatory, approximately 4,398,443 new cases of cancer were detected across Europe in 2020. Among these, 2,339,617 new cases were diagnosed in the Europe male population. The most common types of cancer diagnosed in Europe in 2020 were breast cancer accounting for 12.07% of the total cases. Thus, the increasing prevalence of breast cancer cases is boosting the demand for capecitabine to control the spreading of breast cancer. This prominent factor is amplifying the market growth.

By End-User :

The end user segment is categorized into hospitals, specialty clinics, homecare, and others. In 2022, the hospitals segment accounted for the highest market share of 48.50% in the overall capecitabine market. Capecitabine has been approved for utilization by various international nodal agencies such as the United States Food and Drug Administration (FDA), European Union, and others. Capecitabine is a crucial component of several cancer chemotherapeutic regimens. Thus, capecitabine is deployed in the treatment of various types of cancers in hospitals, including advanced & metastatic breast cancer, colorectal cancers, and others. For instance, in November 2022, the Indian government inaugurated the Homi Bhabha Cancer Hospital in Chandigarh, India. The hospital was built at a cost of over USD 88.6 million and has a total bed capacity of 300 patients at a time. Additionally, in January 2023, the government of Poland invested USD 576.2 million for the expansion of cancer hospitals across the country. Henceforth, the rising development of hospitals providing cancer treatment, including breast cancer, colorectal cancer, and others is expected to increase the adoption of capecitabine in hospitals for the efficient treatment of cancer, thereby, driving the growth of the market in the upcoming years.

However, the specialty clinics segment is expected to be the fastest-growing segment during the forecast period. This growth is attributed to factors such as increasing investment in new specialty clinic facilities, increasing government initiatives, and others.

By Region :

The regional segment includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

In 2022, North America accounted for the highest market share at 38.60% and was valued at USD 393.72 million, and is expected to reach USD 604.17 million in 2030. In North America, the U.S. accounted for the highest market share of 65.50% during the base year of 2022. This growth is attributed to factors such as the increasing prevalence of cancer cases, the rising development of new products, and others. For instance, according to the American Cancer Society, approximately 800 to 900 new cases of osteosarcoma, which is a type of cancer that affects the bone, are identified in the United States each year, among which, half of the cases occur in teenagers and children. Meanwhile, according to the Global Cancer Observatory, approximately 195,499 new cases of cancer including colorectal cancer, lymphoma, lung cancer, and breast cancer among others were recorded in Mexico in 2021. As a result, the increasing prevalence of cancer cases in the North American region is favoring the capecitabine market growth in the region.

Furthermore, Asia Pacific is expected to witness significant growth over the forecast period, growing at a CAGR of 6.1% during 2023-20230. The prime factors such as the presence of key players in the Asia Pacific region, advancement in capecitabine manufacturing, and others are boosting the market growth in the Asia Pacific region.